Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer : Episode 5
Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.
EP: 1.Recent Advances in Endometrial Cancer
EP: 2.Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting
EP: 3.Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer
EP: 4.Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial
Now Viewing
EP: 5.Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
EP: 6.The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer
EP: 7.Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
EP: 8.The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer
EP: 9.Unmet Needs in the Management of Patients With Advanced Endometrial Cancer
EP: 10.Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer
Related Videos
Related Content
